Table 2.
A synergistic interaction between ICI and RT associated with an increased risk of IP in patients with non-small cell lung cancer
| Variables | Cases, N = 46,127 | IP, N = 3830 | Proportion (%), 95% CI | Crude ROR, 95% CI | Adjusteda ROR, 95% CI | P-value |
|---|---|---|---|---|---|---|
| Age (mean/SD) | 65.6 (11.1) | 1.02 (1.02–1.03) | 1.02 (1.02–1.03) | < 0.0001 | ||
| Sex | ||||||
| Female | 17,517 | 1022 | 5.83 (5.49–6.19) | 1 [reference] | 1 [reference] | |
| Male | 23,255 | 2,387 | 10.26 (9.88–10.66) | 1.85 (1.71–1.99) | 1.54 (1.41–1.68) | < 0.0001 |
| Not reported | 5355 | 421 | 7.86 (7.16–8.62) | 1.38 (1.22–1.55) | 0.95 (0.67–1.32) | 0.773 |
| Treatment options | ||||||
| ICI | 19,083 | 2345 | 12.29 (11.83–12.76) | 2.41 (2.25–2.58) | 1.77 (1.64–1.92) | < 0.0001 |
| CHEMO | 9530 | 610 | 6.4 (5.92–6.92) | 0.71 (0.65–0.77) | 0.71 (0.61–0.83) | < 0.0001 |
| TARGET | 11,023 | 621 | 5.63 (5.21–16.08) | 0.59 (0.54–0.65) | 1.18 (1.04–1.33) | 0.008 |
| RT | 519 | 459 | 88.44 (85.30–91.00) | 95.85 (73.71–126.95) | 9.15 (4.07–19.25) | < 0.0001 |
| ICIaCHEMOb | 3110 | 290 | 9.32 (8.34–10.41) | 0.97 (0.79–1.19) | 0.771 | |
| ICIaTARGETb | 227 | 30 | 13.22 (9.23–18.49) | 1.02 (0.65–1.55) | 0.929 | |
| ICIaRTb | 483 | 446 | 92.34 (89.50–94.48) | 13.44 (5.81–33.07) | < 0.0001 | |
IP Interstitial pneumonitis, ROR Reporting odds ratio, SD Standard deviation, RT Radiation therapy, ICI Immune checkpoint inhibitor therapy, CHEMO Chemotherapy, TARGET Molecular targeted therapy
aAge increment was per year for reporting the odds ratio of multivariable logistic regression
bThis row shows the result of the interaction between interstitial pneumonitis and 2 therapies. The P-value for adjusted ROR was calculated using a multivariable logistic regression model. P < 0.05 indicates a significant difference